An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's Disease
The purpose of this study is to determine the long term safety and clinical utility of IPX066 in subjects with Parkinson's Disease.
IPX066 is intended for chronic treatment of motor symptoms for all stages of PD. This study is designed to enroll subjects who have successfully completed one of the following studies of IPX066:
All participants will be given IPX066 for 9 months.
Inclusion Criteria:
Each subject must meet the following inclusion criteria in order to be enrolled in the study:
Exclusion Criteria:
Each subject must be free of the following exclusion criteria in order to be enrolled in the study:
Port Charlotte, Florida 33980, United States
Tampa, Florida 33603, United States
Chicago, Illinois 60611, United States
New Brunswick, New Jersey 08901, United States
Albany, New York 12208, United States
Lublin, Lublin Voivodeship 20-718, Poland
Warsaw, Masovian Voivodeship 02-777, Poland
Mosina, Wielkopoloskie 62-050, Poland
Lasi, Romania 700661, Romania
Dnipropetrovsk, 49005, Ukraine
Donetsk, 83037, Ukraine
Donetsk, 83099, Ukraine
Kharkiv, 61068, Ukraine
Poltava, 36000, Ukraine
Zaporizhzhya, 69035, Ukraine